Search
forLearn
5 / 801 resultslearn Triamcinolone Acetonide
learn ascorbic acid
learn TeraCeutic™
learn hydrocortisone acetate IP
Research
5 / 170 resultsresearch Telogen-sparing arthroconidia involvement in an adult case of endothrix tinea capitis
A rare scalp infection in a 66-year-old woman was successfully treated, leading to full hair regrowth.
research Clinical and Microscopic Evaluation of Dermatophytosis in Suspected Feline Cases
Dermatophytosis is common in young, male Shirazi Persian cats, affecting ears, face, and abdomen.
research Clinico-mycological profile and trichoscopic findings among pediatric tinea capitis patients: A cross-sectional study from northern India (Haryana)
Trichoscopy is a valuable, quick, and non-invasive tool for diagnosing tinea capitis in children.
research Identification of the causative dermatophyte of tinea capitis in children attending Mbarara Regional Referral Hospital in Uganda by PCR-ELISA and comparison with conventional mycological diagnostic methods
PCR-ELISA is better for identifying the fungus causing scalp infections in Ugandan children than traditional methods.
research Tinea Capitis Caused by Microsporum ferrugineum in an Infant during the First Year of Life
Griseofulvin effectively treats tinea capitis in infants.
Community Join
5 / 1000+ resultscommunity Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community can someone help me identify these pls
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.